Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NEU1 | Q99519 | 8/20 | 0.70 |
| ▸ | NEU2 | Q9Y3R4 | 9/20 | 0.67 |
| ▸ | NEU3 | Q9UQ49 | 7/20 | 0.67 |
| ▸ | NEU4 | Q8WWR8 | 7/20 | 0.67 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20568077 | 1.00 | NEU1 (0.70) | NEU1NEU2NEU3NEU4LMNA | |
| SCHEMBL20568235 | 0.96 | NEU2 (0.71) | NEU1NEU2NEU3NEU4LMNA | |
| SCHEMBL20568236 | 0.96 | NEU2 (0.71) | NEU1NEU2NEU3NEU4LMNA | |
| SCHEMBL6018157 | 0.90 | NEU2 (0.78) | NEU1NEU2NEU3NEU4LMNA | |
| SCHEMBL20567927 | 0.87 | NEU2 (0.71) | NEU1NEU2NEU3NEU4LMNA | |
| SCHEMBL8563443 | 0.86 | NEU2 (0.69) | NEU1NEU2NEU3NEU4LMNA | |
| SCHEMBL8560133 | 0.86 | NEU2 (0.69) | NEU1NEU2NEU3NEU4LMNA | |
| SCHEMBL8563620 | 0.86 | NEU2 (0.69) | NEU1NEU2NEU3NEU4LMNA | |
| SCHEMBL2631658 | 0.86 | NEU2 (0.73) | NEU1NEU2NEU3NEU4LMNA | |
| SCHEMBL28036256 | 0.86 | NEU2 (0.73) | NEU1NEU2NEU3NEU4LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220110919-A1 | METHODS OF MODULATING LEUKOCYTES ACTIVATION AND THROMBOCYTE CLEARANCE WITH INHIBITORS OF SPECIFIC NEURAMINIDASE ISOENZYMES | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2022-04-14 | — | — | US | disclosed |
| EP-3886836-A1 | METHODS OF MODULATING LEUKOCYTES ACTIVATION AND THROMBOCYTE CLEARANCE WITH INHIBITORS OF SPECIFIC NEURAMINIDASE ISOENZYMES | The Governors of the University of Alberta (CA) | 2021-10-06 | — | — | EP | disclosed |
| WO-2020107124-A1 | METHODS OF MODULATING LEUKOCYTES ACTIVATION AND THROMBOCYTE CLEARANCE WITH INHIBITORS OF SPECIFIC NEURAMINIDASE ISOENZYMES | PCHEJETSKI ALEXEY (CA) | 2020-06-04 | — | — | WO | disclosed |
| EP-3630740-A1 | METHODS OF PREVENTING OR TREATING ATHEROSCLEROSIS WITH INHIBITORS OF SPECIFIC ISOENZYMES OF HUMAN NEURAMINIDASE | The Governors of the University of Alberta (CA) | 2020-04-08 | — | — | EP | disclosed |
| WO-2018213933-A1 | METHODS OF PREVENTING OR TREATING ATHEROSCLEROSIS WITH INHIBITORS OF SPECIFIC ISOENZYMES OF HUMAN NEURAMINIDASE | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2018-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220110919-A1 | METHODS OF MODULATING LEUKOCYTES ACTIVATION AND THROMBOCYTE CLEARANCE WITH INHIBITORS OF SPECIFIC NEURAMINIDASE ISOENZYMES | NEU1, NEU4, NEU3 | NEU1 1/4885NEU2 5/4885NEU3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.